VaxInnate adds to senior management team
The additions include promoting Lynda Tussey to chief scientific officer from vice president of research and development.
"Dr. Tussey has been an invaluable asset during her time at VaxInnate, with a deep background in immune modulation that she has applied to our proprietary vaccine programs," Wayne F. Pisano, VaxInnate's president and chief executive officer, said. "In her new role as chief scientific officer, she will be responsible for developing the long-term clinical growth plan to enrich the company's pipeline while also devoting resources to our ongoing influenza, dengue and C. diff programs, and leading VaxInnate's discovery efforts."
Bruce Weaver was named the new vice present of manufacturing. He was previously the director of process development. Peter Fusco joined VaxInnate as the vice president of research and development; and Dr. Stephen Haworth became the vice president of clinical. All three will be part of the senior management team at the company.
"Peter Fusco and Stephen Haworth's combined experience in global infectious diseases will be a strong addition for us here at VaxInnate, not only as we advance our current clinical programs, but also in the evaluation of new infectious disease targets that may benefit from the reproducibility, reliability and speed of our proprietary vaccine production technology," Tussey said. "Bruce Weaver's background in recombinant protein vaccine production using our E. coli fermentation and purification methods will be essential to this process. We look forward to employing the significantly expanded depth and creativity of this team as we execute on our lead programs while working to identify additional indications for our pipeline."